Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-05-11
ICR Author
Marsden,
Author
Barr, PM
Brown, JR
Hillmen, P
O'Brien, S
Barrientos, JC
Reddy, NM
Coutre, S
Mulligan, SP
Jaeger, U
Furman, RR
Cymbalista, F
Montillo, M
Dearden, C
Robak, T
Moreno, C
Pagel, JM
Burger, JA
Suzuki, S
Sukbuntherng, J
Cole, G
James, DF
Byrd, JC
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Key Points Higher ibrutinib DI is associated with improved PFS, independent of del17p or TP53 mutation. Ibrutinib hold for >1 week, often needed to manage adverse events, is associated with increased PFS events.
URI
https://repository.icr.ac.uk/handle/internal/1544
DOI
https://doi.org/10.1182/blood-2016-12-737346
Collections
  • Other ICR Research
Language
eng
License start date
2017-05-11
Citation
Blood, 2017, 129 (19), pp. 2612 - 2615
Publisher
American Society of Hematology

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.